Prescribing Vilazodone

Why Vilazodone Matters (and Why It Mostly Doesn't)

Vilazodone is a serotonin reuptake inhibitor that is also a 5-HT1A partial agonist, in effect an SSRI with buspirone bolted on inside a single pill. When it launched in 2011, the marketing promised faster onset, better anxiety coverage, and fewer sexual side effects, all from that 5-HT1A mechanism. On paper it looked like a smarter serotonergic antidepressant.

None of those advantages held up to rigorous scrutiny. Head-to-head against citalopram, vilazodone was no more effective, no faster, and no cleaner sexually. Its NNT for response is about 8, squarely average. It has a real food-absorption requirement, a meaningful CYP3A4 interaction, and a GI side-effect burden (nausea, diarrhea) that limits its use in anxiety. It failed to prevent relapse in its own continuation trial, and it has no data for treatment-resistant depression.

It still gets a guide because vilazodone is now a cheap generic (patent expired June 2022, roughly $40/month) and keeps one narrow, defensible niche: the patient who responds to serotonergic antidepressants, wants to try something with a possible edge on sexual side effects, and has already been through the better-established options. For that patient, with realistic expectations, it's a reasonable second- or third-line agent. As a first-line MDD drug chosen on the strength of its original marketing, it disappoints.

Part 1: Indications

FDA-Approved Use

• Major depressive disorder (MDD) in adults (approved January 2011), its only FDA-approved indication.

Off-Label / Evidence-Adjacent Uses

• Anxious depression: its best-supported clinical use. In the pivotal trials for depression, roughly 82% of enrolled patients met criteria for anxious depression, and vilazodone improved both anxiety and depressive symptoms in that subgroup. But in depressed patients citalopram was the more effective anxiolytic, so this is not a reason to pick vilazodone over a generic SSRI.
• Generalized anxiety disorder (GAD): positive in three large RCTs (20–40 mg/day, mean about 31 mg), but with a small effect size and poor tolerability (nausea and diarrhea drove dropouts). Not a first-choice GAD drug.
• Social anxiety disorder: one small industry-sponsored positive trial with high dropout; a larger confirmatory study was abandoned. The evidence is thin.

Where Vilazodone Does Not Belong

• Treatment-resistant depression. There are no supporting data, and two switch studies in SSRI/SNRI non-responders cast doubt on its value here. Don't reach for vilazodone as a TRD strategy.
• Nonanxious depression. In the anxious-depression subgroup analysis, there was no efficacy signal in the nonanxious group.
• Relapse prevention as a stated goal. In its enriched continuation trial (responders randomized to drug versus placebo), vilazodone did not separate from placebo; it failed to prevent relapse. That raises real questions about durability, and it is one of the more damning facts in its file.

Realistic Role in the Algorithm

Think of vilazodone as a second- or third-line serotonergic antidepressant, chosen after generic SSRIs have failed or been poorly tolerated, and typically after bupropion and vortioxetine have been considered for the sexual-side-effect-conscious patient.

Part 2: Before You Start: Workup and Candidacy

Vilazodone requires no specific baseline labs, no ECG, and no drug levels. Standard depression-care assessment applies:

• Screen for bipolarity before starting any antidepressant monotherapy (activation/switch risk).
• If you're choosing vilazodone for a hoped-for sexual advantage, document baseline sexual function; otherwise you can't tell whether you achieved anything. A brief scale (ASEX or CSFQ) is ideal.
• Review the medication list for CYP3A4 inhibitors and inducers (see Part 7) and for other serotonergic agents/MAOIs.
• Confirm the patient can and will take it with food every day. This is not optional (see Part 3).

Who Is a Poor Candidate?

• Anyone who often takes medication on an empty stomach or skips meals: absorption is too food-dependent.
• Patients on strong CYP3A4 inhibitors that can't be changed.
• Patients whose depression is nonanxious and who have simpler, cheaper first-line options untried.
• Patients needing a treatment-resistance strategy: vilazodone has no evidence there.

Part 3: How to Start and Dose

Formulation

Oral tablets only, in 10 mg, 20 mg, and 40 mg strengths, now available as a generic.

Take It With Food

Vilazodone must be taken with food. On an empty stomach, exposure falls by about 50% and peak concentration by about 60%, which can leave the drug subtherapeutic with no obvious cause. A meal, or at least a substantial snack, reliably improves and normalizes absorption. This single instruction is non-negotiable, and it is the most important thing you will say about this drug.

Starting Dose and Titration

The titration exists mainly to manage nausea, not to chase efficacy:

• Start: 10 mg once daily with food × 7 days.
• Increase to 20 mg once daily with food × 7 days.
• Then 40 mg once daily with food if a higher dose is warranted.
• Target/maintenance: 20–40 mg/day.
• Maximum: 40 mg/day.

The Dose-Response Problem

Vilazodone does not show a clear dose-response, and that should shape how you prescribe it. In the large citalopram head-to-head trial (n=1,133), 20 mg and 40 mg were about equivalent, with no evidence of added benefit at 40 mg. With vortioxetine, pushing the dose can buy real efficacy. With vilazodone, raising the dose above 20 mg mostly buys side effects, not response.

When to Judge Response

• Early improvement (weeks 1–2) appears in some trials, but most antidepressants show it too, so ignore the "faster onset" claim.
• Remission takes about 6 full weeks to separate from placebo. Give an adequate trial of 6 weeks at a therapeutic dose before calling it a failure.

Dose Adjustments and Special Populations

• CYP3A4 interactions: with a strong 3A4 inhibitor (ketoconazole, clarithromycin, etc.), cap the dose at 20 mg/day. With a strong 3A4 inducer (carbamazepine, rifampin) taken for ≥14 days, the dose may be increased up to a maximum of 80 mg/day over 1–2 weeks; return to the usual 40 mg ceiling when the inducer is stopped.
• Hepatic / renal impairment: no dose adjustment for renal or hepatic impairment at any degree, mild through severe.
• Geriatric: no specific dose adjustment.
• Pediatric: not FDA-approved (pediatric MDD trials did not separate from placebo).

Stopping and Switching

• Discontinuation: taper gradually (particularly from 20–40 mg) to reduce discontinuation symptoms.
• MAOI washout: allow 14 days in each direction between vilazodone and an MAOI.

Part 4: Monitoring

There is little to monitor pharmacologically. No labs, no levels, and no ECG are required, so monitoring is clinical.

Part 5: Side Effects and How to Manage Them

Vilazodone's side effects are largely those of an SSRI. The 5-HT1A partial agonism does not deliver the cleaner tolerability that was promised.

Gastrointestinal: the Dominant Issue

• Nausea: dose-dependent, usually early and transient. Taking it with food, already mandatory for absorption, also helps. Slow the titration if needed.
• Diarrhea: more of a problem than with some SSRIs, and an important reason for dropout in the anxiety trials specifically. It is usually mild but can be limiting. The mechanism is the serotonergic (5-HT4) GI stimulation common to the class.

Management: take with food, titrate slowly (the 10→20→40 schedule exists for this), and reassure that nausea typically fades over the first week or two. Persistent diarrhea that doesn't settle is a reason to switch.

CNS

• Dizziness: transient, early.
• Insomnia: can be lasting; if it persists, consider morning dosing or, if intolerable, switching agents.

Sexual Dysfunction: the Debunked Selling Point

The original marketing oversold this, so the details matter.

• Early "low sexual side effects" claims rested on a flawed study design that enrolled patients with pre-existing dysfunction, a poor way to detect new-onset problems.
• The rates in the label, pooled from the placebo-controlled depression studies, are the ordinary serotonergic ones:
  • Men: decreased libido 3% at 20 mg and 4% at 40 mg, abnormal orgasm 2% at either dose, erectile dysfunction 3% at 40 mg, ejaculation disorder 1% to 2%, against 1% or less on placebo.
  • Women: decreased libido 2% and abnormal orgasm 1% at either dose, against 1% or less on placebo.
• The citalopram head-to-head was never designed to settle the question. Its sexual-function analyses were post hoc and descriptive, no inferential statistics were run, and the authors state the trial was not powered to compare treatment groups. Sexual adverse events were reported slightly more often on active treatment than on placebo and most often on citalopram, which is a numerical pattern rather than a demonstrated advantage.

Bottom line: vilazodone's sexual liability is comparable to an SSRI, not clearly better. Do not promise patients a sexual advantage you can't deliver.

Management of Emergent Sexual Dysfunction

If TESD emerges on vilazodone and is unacceptable, the cleanest move is to switch to bupropion (best for sexual side effects) rather than adding it or hoping the 5-HT1A mechanism will rescue you, which it won't.

Other (Class-Level, Sparsely Studied for This Drug Specifically)

• Hyponatremia / SIADH: an SSRI-class risk; watch in the elderly and those on diuretics.
• Bleeding risk: serotonergic agents mildly impair platelet aggregation; caution with NSAIDs, anticoagulants, antiplatelets.
• Osteopenia and withdrawal: raised as class concerns but with scant vilazodone-specific data.

Part 6: Overdose, Toxicity, and Boxed Warnings

Overdose

Dedicated overdose data are limited, but vilazodone behaves like other serotonergic antidepressants: it lacks the cardiotoxic lethality of tricyclics, and management is supportive. The principal specific risk is serotonin syndrome, which is low with vilazodone alone but rises sharply in combination with other serotonergic agents (MAOIs, linezolid, other antidepressants, triptans, tramadol). Know the triad (autonomic instability, neuromuscular hyperactivity including clonus and hyperreflexia, and altered mental status) and treat serotonin syndrome as an emergency.

There is no drug-level test and no antidote; care is symptomatic.

Part 7: Drug Interactions

Vilazodone's interaction profile has two clinically important features (one metabolic, one pharmacodynamic), plus the food effect already covered.

CYP3A4: the Interaction That Changes Dosing

Vilazodone is primarily a CYP3A4 substrate.

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice) can increase vilazodone exposure by roughly 50%. With a strong inhibitor on board, cap the dose at 20 mg/day and counsel patients to avoid grapefruit.
• Strong CYP3A4 inducers (e.g., carbamazepine, rifampin, phenytoin, St. John's wort) can lower vilazodone levels and blunt efficacy; a higher dose (increased up to 2-fold, to a maximum of 80 mg/day, over 1 to 2 weeks of co-administration) may be considered, reverting when the inducer stops.

Serotonergic Combinations: Serotonin Syndrome

• MAOIs: contraindicated. Observe a 14-day washout in both directions.
• Other serotonergics (SSRIs/SNRIs, linezolid, methylene blue, triptans, tramadol, St. John's wort): additive serotonin-syndrome risk; combine cautiously and counsel patients.

Other

• CNS depressants (alcohol, benzodiazepines, opioids): additive sedation/impairment.
• Bleeding: additive risk with NSAIDs/anticoagulants/antiplatelets (class serotonergic effect).
• Vilazodone is not a significant CYP inhibitor itself, so it is unlikely to raise the levels of other drugs meaningfully.

Part 8: Special Populations

Pregnancy

Data are limited. Vilazodone falls under the old FDA Pregnancy Category C framework. Individualize based on illness severity and the risk of untreated depression, and prefer agents with more reproductive-safety data (e.g., sertraline) when a serotonergic antidepressant is needed in pregnancy. As with all serotonergic antidepressants used near term, be alert to neonatal adaptation syndrome and to persistent pulmonary hypertension of the newborn (PPHN).

Lactation

Very limited data; most authorities lean toward better-characterized alternatives when breastfeeding. If used, monitor the infant clinically.

Elderly

No dedicated geriatric efficacy data. Apply standard principles: start low, titrate slowly, watch for hyponatremia (especially with diuretics), fall/dizziness risk, and polypharmacy interactions (particularly CYP3A4). There is no specific age-based dose cap, but there is rarely a compelling reason to reach for vilazodone first in an older patient.

Renal Impairment

No dose adjustment is required at any degree of renal impairment. The label covers mild through severe impairment, a glomerular filtration rate of 15 to 90 mL/min.

Hepatic Impairment

No dose adjustment is required at any degree of hepatic impairment. The label covers mild through severe impairment, a Child-Pugh score of 5 to 15. Vilazodone is still cleared by CYP3A4, so the interaction profile applies.

Children and Adolescents

Not FDA-approved for pediatric depression (only fluoxetine and escitalopram are). Use off-label only after first-line SSRIs fail, and only with full attention to the boxed suicidality warning, which weighs most heavily in adolescents.

Part 9: Discontinuation and Taper

Vilazodone has a half-life of about 25 hours, long enough to soften discontinuation symptoms but not to eliminate them. Expect an intermediate withdrawal risk: flu-like symptoms, paresthesias, dizziness, and mood/sleep disturbance if stopped abruptly, similar to a moderate-half-life SSRI.

How to Stop

• Taper over about 2–4 weeks rather than stopping abruptly (e.g., step down 40 → 20 → 10 mg, about a week at each step, slower if symptoms emerge).
• Monitor for dizziness, mood destabilization, and sleep disturbance during the taper.
• Go slower in patients who have been on it long-term or who are sensitive to serotonergic discontinuation.

Part 10: Vilazodone vs the Alternatives

Vilazodone compares poorly with the alternatives, so patient and drug selection matter.

• vs generic SSRIs (e.g., citalopram, escitalopram, sertraline): Head-to-head, vilazodone was no more effective and no faster than citalopram, with comparable sexual side effects and a greater food/GI burden. SSRIs are cheaper, better-characterized, and don't require a meal for absorption. For most patients, an SSRI wins.
• vs bupropion (for sexual side effects): Bupropion is the clear choice when sexual tolerability is the priority: it has low rates of sexual dysfunction, causes no weight gain, and is activating. Vilazodone's sexual advantage is unproven; bupropion's is real.
• vs vortioxetine: Both are newer serotonergic "designer" agents with unproven superiority and higher (formerly) brand cost. Vortioxetine has narrow, contested cognitive-domain signals and can be dose-escalated for benefit; vilazodone cannot. Neither is clearly better than a generic SSRI.
• vs mirtazapine: For depression with prominent insomnia/appetite loss, mirtazapine is more targeted (and doesn't need food timing), at the cost of weight gain and sedation.

So why use it at all? Two legitimate reasons remain: it's now a cheap generic, and in the anxious-depression patient who has already cycled through better-established options and wants to try another serotonergic agent, it's a reasonable next step. The case is modest and real.

Mechanism

Vilazodone is a SPARI (Serotonin Partial Agonist and Reuptake Inhibitor):

• Serotonin reuptake inhibition (the SSRI component), plus
• 5-HT1A partial agonism (the buspirone-like component).

The theory was that adding 5-HT1A partial agonism to serotonin reuptake inhibition, an SSRI plus buspirone in one tablet, would desensitize the 5-HT1A autoreceptor faster (speeding onset), improve anxiety, and reduce sexual side effects. None of these theoretical benefits survived rigorous testing. There was no faster onset, no clear anxiety advantage over SSRIs, and no clean sexual advantage.

• Half-life: about 25 hours (supports once-daily dosing).
• Metabolism: primarily hepatic via CYP3A4 (hence the interaction and the grapefruit effect); vilazodone is not itself a meaningful CYP inhibitor.

The Bedside Cheat Sheet